Natalie C Kegulian1, Bastian Ramms2,3, Steven Horton1, Olgica Trenchevska4, Dobrin Nedelkov4, Mark J Graham5, Richard G Lee5, Jeffrey D Esko2,6, Hussein N Yassine1, Philip L S M Gordts2,6. 1. From the Department of Medicine, University of Southern California, Los Angeles (N.C.K., S.H., H.N.Y.). 2. Department of Medicine (B.R., J.D.E., P.L.S.M.G.), University of California San Diego, La Jolla. 3. Department of Chemistry, Biochemistry I, Bielefeld University, Germany (B.R.). 4. The Biodesign Institute, Arizona State University, Tempe (O.T., D.N.). 5. Ionis Pharmaceuticals, Carlsbad, CA (M.J.G., R.G.L.). 6. Glycobiology Research and Training Center (J.D.E., P.L.S.M.G.), University of California San Diego, La Jolla.
Abstract
OBJECTIVE: ApoC-III (apolipoprotein C-III) glycosylation can predict cardiovascular disease risk. Higher abundance of disialylated (apoC-III2) over monosialylated (apoC-III1) glycoforms is associated with lower plasma triglyceride levels. Yet, it remains unclear whether apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC-III antisense therapy (volanesorsen) affects distribution of apoC-III glycoforms. Approach and Results: To measure the abundance of human apoC-III glycoforms in plasma over time, human TRLs were injected into wild-type mice and mice lacking hepatic TRL clearance receptors, namely HSPGs (heparan sulfate proteoglycans) or both LDLR (low-density lipoprotein receptor) and LRP1 (LDLR-related protein 1). ApoC-III was more rapidly cleared in the absence of HSPG (t1/2=25.4 minutes) than in wild-type animals (t1/2=55.1 minutes). In contrast, deficiency of LDLR and LRP1 (t1/2=56.1 minutes) did not affect clearance of apoC-III. After injection, a significant increase in the relative abundance of apoC-III2 was observed in HSPG-deficient mice, whereas the opposite was observed in mice lacking LDLR and LRP1. In patients, abundance of plasma apoC-III glycoforms was assessed after placebo or volanesorsen administration. Volanesorsen treatment correlated with a statistically significant 1.4-fold increase in the relative abundance of apoC-III2 and a 15% decrease in that of apoC-III1. The decrease in relative apoC-III1 abundance was strongly correlated with decreased plasma triglyceride levels in patients. CONCLUSIONS: Our results indicate that HSPGs preferentially clear apoC-III2. In contrast, apoC-III1 is more effectively cleared by LDLR/LRP1. Clinically, the increase in the apoC-III2/apoC-III1 ratio on antisense lowering of apoC-III might reflect faster clearance of apoC-III1 because this metabolic shift associates with improved triglyceride levels.
OBJECTIVE: ApoC-III (apolipoprotein C-III) glycosylation can predict cardiovascular disease risk. Higher abundance of disialylated (apoC-III2) over monosialylated (apoC-III1) glycoforms is associated with lower plasma triglyceride levels. Yet, it remains unclear whether apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC-III antisense therapy (volanesorsen) affects distribution of apoC-III glycoforms. Approach and Results: To measure the abundance of human apoC-III glycoforms in plasma over time, human TRLs were injected into wild-type mice and mice lacking hepatic TRL clearance receptors, namely HSPGs (heparan sulfate proteoglycans) or both LDLR (low-density lipoprotein receptor) and LRP1 (LDLR-related protein 1). ApoC-III was more rapidly cleared in the absence of HSPG (t1/2=25.4 minutes) than in wild-type animals (t1/2=55.1 minutes). In contrast, deficiency of LDLR and LRP1 (t1/2=56.1 minutes) did not affect clearance of apoC-III. After injection, a significant increase in the relative abundance of apoC-III2 was observed in HSPG-deficient mice, whereas the opposite was observed in mice lacking LDLR and LRP1. In patients, abundance of plasma apoC-III glycoforms was assessed after placebo or volanesorsen administration. Volanesorsen treatment correlated with a statistically significant 1.4-fold increase in the relative abundance of apoC-III2 and a 15% decrease in that of apoC-III1. The decrease in relative apoC-III1 abundance was strongly correlated with decreased plasma triglyceride levels in patients. CONCLUSIONS: Our results indicate that HSPGs preferentially clear apoC-III2. In contrast, apoC-III1 is more effectively cleared by LDLR/LRP1. Clinically, the increase in the apoC-III2/apoC-III1 ratio on antisense lowering of apoC-III might reflect faster clearance of apoC-III1 because this metabolic shift associates with improved triglyceride levels.
Entities:
Keywords:
apolipoproteins; cardiovascular diseases; glycoproteins; mass spectrometry; triglycerides
Authors: Jennifer M MacArthur; Joseph R Bishop; Kristin I Stanford; Lianchun Wang; André Bensadoun; Joseph L Witztum; Jeffrey D Esko Journal: J Clin Invest Date: 2007-01 Impact factor: 14.808
Authors: S Lund-Katz; M Zaiou; S Wehrli; P Dhanasekaran; F Baldwin; K H Weisgraber; M C Phillips Journal: J Biol Chem Date: 2000-11-03 Impact factor: 5.157
Authors: Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner Journal: Science Date: 2008-12-12 Impact factor: 47.728
Authors: Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Philip H Links; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Robin J Parks; Yuwei Wang; Zemin Yao Journal: J Lipid Res Date: 2010-01 Impact factor: 5.922
Authors: Carlos O Mendivil; Chunyu Zheng; Jeremy Furtado; Julian Lel; Frank M Sacks Journal: Arterioscler Thromb Vasc Biol Date: 2009-11-12 Impact factor: 8.311
Authors: Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén Journal: Diabetes Date: 2009-06-05 Impact factor: 9.461